Currently out of the existing stock ratings of Edward Tenthoff, 824 are a BUY (91.15%), 69 are a HOLD (7.63%), 11 are a SELL (1.22%).

Edward Tenthoff

Work Performance Price Targets & Ratings Chart

Analyst Edward Tenthoff, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 42.77% that have a potential upside of 53.22% achieved within 292 days.

Edward Tenthoff’s has documented 1,741 price targets and ratings displayed on 95 stocks. The coverage is on Healthcare, Technology, Industrials, Energy, Consumer Cyclical, Basic Materials sectors.

Most recent stock forecast was given on CRSP, Crispr Therapeutics AG at 17-Mar-2026.

Wall Street Analyst Edward Tenthoff

Analyst best performing recommendations are on SKYE (SKYE BIOSCIENCE, COMMON STOCK).
The best stock recommendation documented was for MIST (MILESTONE PHARMACEUTICALS) at 3/23/2020. The price target of $7.69 was fulfilled within 1 day with a profit of $6.31 (45.07%) receiving and performance score of 450.71.

Average potential price target upside

of $501.8 (98.26%) on PTI (PROTEOSTASIS THERAPEUTICS).
of $186 (32.76%) on ELOX (ELOXX PHARMACEUTICALS).
of $93.34 (201.15%) on TPST (TEMPEST THERAPEUTICS).

AGLE Aeglea Bio Therapeutics ALNY Alnylam Pharmaceuticals ALPN Alpine Immune Sciences APVO Aptevo Therapeutics ARAV Aravive ARGX argenx NV ADR ARVN Arvinas ARWR Arrowhead Pharmaceuticals AVEO AVEO Pharmaceuticals BCYC Bicycle Therapeutics Ltd CCXI ChemoCentryx CRSP Crispr Therapeutics AG CYTK Cytokinetics DYN Dyne Therapeutics EXEL Exelixis FATE Fate Therapeutics GMDA Gamida Cell Ltd INFI Infinity Pharmaceuticals IPSC Century Therapeutics KLDO Kaleido Biosciences KYMR Kymera Therapeutics MCRB Seres Therapeutics MRKR Marker Therapeutics MRNA Moderna NVAX Novavax NXTC NextCure OPK Opko Health PSTX Poseida Therapeutics PTI Proteostasis Therapeutics RAPT RAPT Therapeutics STRO Sutro Biopharma SYBX Synlogic SYRS Syros Pharmaceuticals TPST Tempest Therapeutics TTPH Tetraphase Pharmaceuticals XNCR Xencor LIFE aTyr Pharma SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals ARNA Arena Pharmaceuticals ASLN Aslan Pharmaceuticals Ltd ADR CBAY Cymabay Therapeu CHMA Chiasma EIGR Eiger Biopharmaceuticals ELOX Eloxx Pharmaceuticals FULC Fulcrum Therapeutics GNCA Genocea Biosciences JNCE Jounce Therapeutics LEGN Legend Biotech Corp LRMR Larimar Therapeutics MIST Milestone Pharmaceuticals FSTX FStar Therapeutics GLUE Monte Rosa Therapeutics KRON Kronos Bio OMGA Omega Therapeutics PNT POINT Biopharma Global PRTC PureTech Health PLC SBPH Spring Bank Pharmaceuticals VCEL Vericel Corp Ord XOMA XOMA Corp ZFGN Zafgen APTO Aptose Biosciences GILD Gilead Sciences REGN Regeneron Pharmaceuticals SGEN Seagen XLRN Acceleron Pharma GRTS Gritstone Oncology XFOR X4 Pharmaceuticals CFRX ContraFect Corp IDRA Idera Pharmaceuticals KDMN Kadmon Holdings MTNB Matinas BioPharma Holdings ONCS OncoSec Medical MESO Mesoblast Ltd GRTX Galera Therapeutics CUE Cue Biopharma SKYE Skye Bioscience, Common Stock ARRY Array Technologies CAMP CalAmp Corp CAPR Capricor Therapeutics IGMS IGM Biosciences INO Inovio Pharmaceuticals ACRV Acrivon Therapeutics, Common Stock AL Air Lease AP Ampco-Pittsburgh AR Antero Resources Corp AS Amer Sports CRDF Cardiff Oncology CTMX CytomX Therapeutics GM General Motors Company IBRX Immunitybio KRO Kronos Worldwide LENZ LENZ Therapeutics ONVO Organovo Holdings SY So-Young International

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Yanan Zhu (WELLS FARGO)